Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
| Market Cap | 111.20M | P/E | - | EPS this Y | 12.30% | Ern Qtrly Grth | - |
| Income | -6M | Forward P/E | -4.94 | EPS next Y | 33.30% | 50D Avg Chg | 11.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 8.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -17.00% |
| Recommedations | 2.00 | Quick Ratio | 0.14 | Shares Outstanding | 30.71M | 52W Low Chg | 63.00% |
| Insider Own | 9.26% | ROA | -122.71% | Shares Float | 13.61M | Beta | 1.74 |
| Inst Own | 15.02% | ROE | - | Shares Shorted/Prior | 1.65M/417.15K | Price | 6.91 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 110,890 | Target Price | 15.00 |
| Oper. Margin | - | Earnings Date | Oct 23 | Volume | 232,164 | Change | 1.62% |
About BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
BriaCell Therapeutics Corp. News